Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» migraines
migraines
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
BioPharma Dive
Tue, 05/10/22 - 10:57 am
Pfizer
M&A
Biohaven
migraines
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
Fierce Pharma
Tue, 05/3/22 - 10:44 pm
Zosano Pharma
FDA
migraines
migraine patch
M207
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'
Fierce Biotech
Mon, 05/2/22 - 06:19 pm
Axsome Therapeutics
migraines
FDA
AXS-07
It's CRL Day at the FDA as Axsome, Junshi and Coherus Get Bad News
BioSpace
Mon, 05/2/22 - 11:44 am
FDA
complete response letter
Junshi Biosciences
Coherus Biosciences
Axsome Therapeutics
migraines
AXS-07
After culling workforce, migraine biotech Zosano drops lead — and sole — program
Endpoints
Mon, 05/2/22 - 11:00 am
Zosano
migraines
layoffs
M207
Biohaven migraine drug partnered with Pfizer lands twin European approvals
MedCity News
Wed, 04/27/22 - 10:38 pm
Europe
Pfizer
Biohaven
migraines
rimegepant
Axsome expects migraine drug to be rejected as manufacturing issues arise
Endpoints
Mon, 04/25/22 - 10:42 am
Axsome Therapeutics
migraines
FDA
AXS-07
Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission
Fierce Biotech
Thu, 03/17/22 - 11:16 pm
Zosano Pharma
layoffs
migraines
M207
AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up
Fierce Pharma
Thu, 03/10/22 - 10:22 pm
AbbVie
Biohaven
migraines
Qulipta
Nurtec
Tiny pharma hits a new low with FDA refusing to review company's response to its CRL
Endpoints
Tue, 02/22/22 - 10:57 am
Zosano Pharma
FDA
complete response letter
migraines
migraine patch
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
Fierce Pharma
Fri, 02/11/22 - 11:46 am
AbbVie
pharma marketing
migraines
Qulipta
television ads
DTC ads
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
Fierce Pharma
Thu, 02/10/22 - 08:02 pm
AbbVie
Biohaven
migraines
Qulipta
Nurtec ODT
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig
Fierce Pharma
Tue, 02/1/22 - 11:28 pm
Amgen
Novartis
Aimovig
migraines
SEC
Pfizer and Biohaven close collaboration agreements
Pharmaceutical Business Review
Thu, 01/6/22 - 10:54 am
Pfizer
Biohaven
rimegepant
zavegepant
Nurtec ODT
migraines
Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman role
Fierce Biotech
Mon, 12/6/21 - 10:50 am
Biohaven
zavegepant
migraines
Tonix Cleared to Propel Migraine Therapy into Phase II
BioSpace
Tue, 11/23/21 - 08:52 pm
Tonix Pharmaceuticals
clinical trials
TNX-1900
migraines
Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?
Fierce Pharma
Mon, 11/22/21 - 10:21 am
migraines
pharma marketing
JNJ
Topamax
Amgen
Biohaven
Eli Lilly
Teva Pharmaceutical
Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec
Fierce Pharma
Thu, 11/18/21 - 11:03 pm
Eli Lilly
Biohaven
migraines
clinical trials
Nurtec ODT
Emgality
Amid crowded migraine market, Lundbeck goes its own way
Pharmaforum
Mon, 11/15/21 - 10:42 am
Lundbeck
migraines
Lu AG09222
Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility
Endpoints
Fri, 11/12/21 - 10:39 am
Lundbeck
R&D
layoffs
Vyepti
migraines
India
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »